<DOC>
	<DOCNO>NCT00550654</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . PURPOSE : This phase II trial study well conformal radiation therapy work treat patient metastatic cancer outside brain .</brief_summary>
	<brief_title>Conformal Radiation Therapy Treating Patients With Metastatic Cancer Outside Brain</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate local control ( define absence local progression ) treat site metastatic disease patient extracranial oligometastases treat ablative dos highly conformal radiotherapy deliver helical tomotherapy . - To evaluate local control treat site metastatic disease patient . Secondary - To determine median time local progression patient treat regimen . - To evaluate interfraction intrafraction motion megavoltage compute tomography ( CT ) image base site metastasis patient . - To compare tumor growth systemic therapy tumor treat targeted radiotherapy v newly develop tumor treat radiotherapy . - To evaluate treatment hypofractionated highly conformal radiotherapy helical tomotherapy improve pain score decrease need analgesia patient . OUTLINE : Patients stratify accord histology ( renal cell carcinoma v melanoma v sarcoma v histology ) . Patients undergo hypofractionated highly conformal radiotherapy helical tomotherapy every day 5 day total 3 fraction . Patients undergo megavoltage image fraction verify position target lesion . Patients complete pain assessment questionnaire baseline 1 3 month treatment . After completion study therapy , patient follow 1 3 month every 3 month 1 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm cancer No active disease primary site assess physical examination , clinical evaluation , sitespecific image Measurable metastatic disease meeting follow criterion : Four few site extracranial lesion &lt; 5 cm size If metastatic site ( ) within lung , follow criterion must meet : No two metastasis proximal bronchial tree area ( define 2 cm trachea mainstem bronchus ) Carbon monoxide diffuse capacity ( DLCO ) &gt; 30 % predict forced expiratory volume 1 ( FEV1 ) &gt; 1.2 L ( patient one metastatic site lung ) If metastatic site ( ) within 2 cm either kidney , creatinine level must &lt; 1.5 time upper limit normal ( ULN ) If metastatic site ( ) within 2 cm liver , bilirubin level must &lt; 1.5 time ULN Patients metastatic disease meet follow criterion exclude : Proposed site ( ) treatment previously treat radiotherapy Metastatic site ( ) require emergent treatment ( e.g. , spinal cord compression , cauda equina , airway compromise , lifethreatening endorgan dysfunction ) Disease untreated previously treat progressive brain Pathologic fracture impend pathologic fracture metastatic site Metastatic site ( ) disease histology know sensitive low dos radiotherapy ( e.g. , pure seminoma , lymphoma , small cell carcinoma ) Patients surgery deem appropriate option standard care ( e.g. , isolated lung metastasis sarcoma isolate liver metastasis colon cancer ) refuse surgical therapy eligible PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy &gt; 12 week assess consult radiation oncologist Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history lupus erythematosus scleroderma No known hypersensitivity therapeutic radiotherapy No malignancy within past 2 year except nonmelanoma skin cancer situ malignancy cervix , bladder , head neck No unrelated systemic illness , judgment investigator , would compromise patient 's ability tolerate study therapy would likely interfere study procedure result Able likely adhere study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics More 2 week since prior concurrent chemotherapy Prior concurrent hormonal agent , include antiandrogens , gonadotropinreleasing hormone agonist , aromatase inhibitor , tamoxifen , similar agent allow No change systemic therapy 6 week within 4 week initiate study radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>chondrosarcoma</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>lung metastasis</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>bone metastasis</keyword>
</DOC>